24
Jun
2009
Lumavita, AG: Series A $5.5M
Posted in I - Series A, Q - 2Q09, R - INTERNATIONAL, X - HPV, X - HSV, X - Vaginitis
Lumavita (Switzerland) a clinical-stage biopharmaceutical company focused on anti-infectives for women’s health including vaginitis, HPV and HSV, closed a $5.5 Series A bring the total round up to $22M. Participants include HealthCap and Endeavour Vision.
OnBioVC PARTNERS
-
